Tubaki Basavaraj Ramappa, Benni Jyoti Mahadev, Rao Niranjan, Prasad Uchangi Nagaraja Rao
Department of Kayachikitsa, KLEU BMK Ayurveda Mahavidyalaya, Belgaum, Karnataka, India.
Department of Pharmacology, KLEU JN Medical College, Belgaum, Karnataka, India.
Anc Sci Life. 2016 Jul-Sep;36(1):48-55. doi: 10.4103/0257-7941.195406.
This paper explores the role that Ayurveda can play in the management of Iron Deficiency Anaemia, a major nutritional deficiency disorder affecting people across the globe.
Forty (40) patients suffering from Iron deficiency anaemia as per WHO guidelines, between the age group of 20 to 60 yrs of either sex participated in the study. Study was a randomized, controlled, open label clinical study. Patients were randomly divided into two groups: Group D ( = 20) received Dhārī avaleha 10 g twice a day after food. Group K ( = 20) received capsules Kasīsa bhasma 125 mg thrice a day. Both interventions were administered for 30 days and the subjects were followed up for next 30 days with placebo capsules to assess the sustainability of the effects. Assessments were done at baseline, 30 and 60 days. Primary outcome measure was hemoglobin estimation (Hb) and secondary outcome measures were the other hematological parameters such as Red blood cell (RBC) indices, total RBC count, Packed Cell volume (PCV) and Peripheral Blood smear study.
Both interventions produced significant improvements ( < 0.001). was better compared to in terms of primary ( < 0.0001) and secondary outcomes. Comparison of outcomes from base line - 30 day, base line - 60 day and 30 - 60 day showed significant ( < 0.0001) improvement in both the groups in parameters such as haemoglobin, MCV and MCH. Hence improvements sustained during placebo intervened sustainability period also.
Study effectively shows that Kasīsa bhasma is better then . Improvements by both interventions were sustained even during the sustainability period.
本文探讨了阿育吠陀医学在缺铁性贫血管理中可发挥的作用。缺铁性贫血是一种影响全球人群的主要营养缺乏性疾病。
根据世界卫生组织指南，40名年龄在20至60岁之间、患有缺铁性贫血的男女患者参与了该研究。该研究为随机、对照、开放标签的临床研究。患者被随机分为两组：D组（n = 20）每天两次、每次10克饭后服用达里阿瓦莱哈。K组（n = 20）每天三次、每次125毫克服用卡西萨巴斯马胶囊。两种干预措施均持续30天，并在接下来的30天内使用安慰剂胶囊对受试者进行随访，以评估效果的可持续性。在基线、30天和60天时进行评估。主要结局指标是血红蛋白测定（Hb），次要结局指标是其他血液学参数，如红细胞（RBC）指数、红细胞总数、血细胞比容（PCV）和外周血涂片检查。
两种干预措施均产生了显著改善（P < 0.001）。在主要结局（P < 0.0001）和次要结局方面，K组比D组更好。比较基线 - 30天、基线 - 60天和30 - 60天的结局，两组在血红蛋白、平均红细胞体积（MCV）和平均红细胞血红蛋白含量（MCH）等参数上均有显著改善（P < 0.0001）。因此，在安慰剂干预的可持续性期间，改善效果也得以维持。
研究有效表明，卡西萨巴斯马比达里阿瓦莱哈更好。即使在可持续性期间，两种干预措施带来的改善效果也得以维持。
